Astrana Health Q3 2026 Earnings: Operating Profit More than Doubles

Astrana Health (NASDAQ: ASTH) reported Q3 2026 revenue of $1,023.6 million, up 7% from $956.0 million, while diluted EPS rose to $0.26 from $0.01. Operating income more than doubled to $39.9 million, led by Care Partners, and adjusted EBITDA increased 13% to $77.2 million. For the nine months ended September 30, operating cash flow remained nearly flat despite higher earnings.

Core Earnings Data

Revenue growth translated into stronger operating leverage because cost of services increased less than sales. Cost of services rose to $900.1 million from $858.9 million, while depreciation and amortization was nearly unchanged; general and administrative expenses increased to $68.0 million from $62.4 million. As a result, operating margin expanded to approximately 3.9% from 2.0%.

The difference between GAAP and adjusted growth was substantial: GAAP diluted EPS increased by $0.25, but adjusted EPS rose only 4%. That distinction is important because the prior-year quarter included considerably more costs and other items excluded from the company’s adjusted results.

Business and Segment Performance

Care Partners remained Astrana’s primary revenue and operating profit contributor, with its revenue increasing 8% and operating income rising 94%. Care Delivery remained loss-making, while Care Enablement produced $24.4 million of operating income on 5% revenue growth. At the revenue-category level, a $73.3 million increase in capitation revenue more than accounted for the company’s $67.6 million consolidated revenue increase, offsetting declines in risk-pool settlements, management fees, and fee-for-service revenue.

Segment revenue included $128.2 million of intersegment eliminations. Corporate costs of $32.1 million also reduced segment-level earnings to the consolidated operating income total.

Profitability, Cash Flow, and the Balance Sheet

The improvement in operating profit reflected better service-cost leverage. Total expenses rose to $983.7 million from $936.8 million, an increase of $46.9 million compared with a $67.6 million increase in revenue. Net other expense also improved to $7.7 million from $13.5 million, partly because quarterly interest expense declined to $15.0 million from $17.7 million.

Cash generation did not rise alongside earnings. For the first nine months of 2026, operating cash flow was $117.1 million, essentially unchanged from $117.5 million a year earlier. Free cash flow declined approximately 5% to $105.4 million as capital expenditures increased to $11.7 million from $7.0 million. Changes in operating assets and liabilities used $18.8 million of cash, compared with providing $36.1 million in the prior-year period.

Cash and cash equivalents declined to $396.2 million at September 30 from $429.5 million at the end of 2025. At the same time, total current and long-term debt fell to approximately $925.4 million from $1.039 billion, supported by $115.9 million of debt repayments during the first nine months. Receivables increased to $530.9 million from $374.5 million, contributing to the importance of working-capital conversion in future quarters.

Why GAAP EPS Rose Much Faster than Adjusted EPS

Astrana’s GAAP profit increase reflected both genuine operating improvement and a much easier comparison with the prior-year quarter. The adjusted EBITDA reconciliation added back only $3.8 million of “other, net” items in Q3 2026, compared with $26.3 million in Q3 2025. The prior-year amount included a $13.0 million legal matter and acquisition-related costs, including $12.7 million connected with the Prospect transaction.

Stock-based compensation moved in the opposite direction, rising to $15.6 million from $7.7 million. After excluding these and other items, adjusted net income attributable to Astrana increased to $35.2 million from $33.8 million, explaining why adjusted EPS growth was limited to 4% even as GAAP EPS rose sharply. The doubling of operating income nevertheless shows that the quarter’s improvement was not solely the result of adjustments.

2026 Guidance

Astrana introduced Q4 guidance and narrowed its full-year ranges for revenue, adjusted EBITDA, and free cash flow. The earlier full-year ranges were not included in the supplied release, so the extent of the narrowing cannot be quantified from the available information.

The entire Q4 adjusted EBITDA range is below the $77.2 million generated in Q3, pointing to an expected sequential decrease. The company did not provide a specific explanation for that anticipated change in the earnings release.

Management Perspective and 2027 Expansion

Management attributed the quarter’s performance to Astrana’s physician partnerships, integrated care model, and technology platform while emphasizing continued investment in growth. Several recently announced operating developments are focused on periods after Q3 rather than the reported quarter.

Astrana closed the acquisition of an independent practice association in Georgia on October 1. It also added two Care Enablement clients—a Connecticut provider group and a California hospital—that are expected to join its technology and managed-services platform in early 2027. New Medicare Advantage payer partnerships in Southern California, Texas, and Arizona are scheduled to take effect on January 1, 2027.

Risks Investors Should Watch

• Cash conversion has lagged earnings growth. Nine-month operating cash flow was nearly flat and free cash flow declined, while receivables increased by $156.4 million from year-end.
• Adjusted earnings growth was modest. Adjusted EPS increased only 4%, and quarterly stock-based compensation rose to $15.6 million from $7.7 million.
• Care Delivery remains unprofitable. The segment reported a $1.6 million operating loss, while consolidated results also absorbed $32.1 million of corporate costs.
• Debt and interest expense remain meaningful. Astrana reduced debt during the first nine months, but total debt was still approximately $925.4 million and Q3 interest expense was $15.0 million.
• Q4 guidance implies lower adjusted EBITDA. Even the high end of the Q4 range is below the Q3 result, creating an execution point for the final quarter of 2026.

Summary

Astrana’s Q3 2026 results combined 7% revenue growth with substantially better operating leverage, driven primarily by Care Partners and higher capitation revenue. GAAP profit rose much faster than adjusted earnings because the prior-year comparison contained heavier excluded costs, while cash flow remained comparatively restrained by working-capital movements and higher capital spending. Investors’ next focus will be the expected Q4 decline in adjusted EBITDA, cash conversion, Care Delivery profitability, and the onboarding of new partnerships and clients in 2027.